SCHEMBL4582931

SCHEMBL4582931

CC(C)Cn1c(N)nc2ccc(-c3c(-c4ccccc4)nc(-c4ccc(Cl)cc4)n3C)cc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 2/20 0.51
MAP4K4 O95819 2/20 0.51
ERBB2 P04626 2/20 0.51
PIM1 P11309 2/20 0.51
MAPK8 P45983 2/20 0.51
MAPK9 P45984 2/20 0.51
CSNK1D P48730 2/20 0.51
MAP4K2 Q12851 2/20 0.51
CAMK2B Q13554 2/20 0.51
CAMK2G Q13555 2/20 0.51
DYRK1A Q13627 2/20 0.51
ERBB4 Q15303 2/20 0.51
PIM3 Q86V86 2/20 0.51
MINK1 Q8N4C8 2/20 0.51
PRKD2 Q9BZL6 2/20 0.51
MKNK2 Q9HBH9 2/20 0.51
DYRK3 O43781 1/20 0.51
FGFR1 P11362 1/20 0.51
FLT4 P35916 1/20 0.51
FRK P42685 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL990654 0.80 MAPK14 (0.55) PRKD3MAP4K4ERBB2PIM1MAPK8
SCHEMBL989440 0.77 MAPK14 (0.55) PRKD3MAP4K4ERBB2PIM1MAPK8
SCHEMBL991919 0.74 MAPK14 (0.51) PRKD3MAP4K4ERBB2PIM1MAPK8
SCHEMBL989496 0.74 MAPK14 (0.57) PRKD3MAP4K4ERBB2PIM1MAPK8
SCHEMBL29594245 0.72 MAPK14 (0.54) DYRK1AMAPK14ALDH1A1SMN1; SMN2CYP1A2
SCHEMBL4069800 0.72 MAPK14 (0.54) DYRK1AMAPK14ALDH1A1SMN1; SMN2CYP1A2
SCHEMBL5989721 0.72 MAPK14 (0.51) PRKD3MAP4K4ERBB2PIM1MAPK8
SCHEMBL991427 0.72 MAPK14 (0.50) PRKD3MAP4K4ERBB2PIM1MAPK8
SCHEMBL989236 0.71 MAPK14 (0.46) PRKD3MAP4K4ERBB2PIM1MAPK8
SCHEMBL990057 0.71 MAPK14 (0.67) PRKD3MAP4K4ERBB2PIM1MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227839-A1 Kinase Inhibitors ELI LILLY AND COMPANY 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227839-A1 Kinase Inhibitors ABL1, MAP3K20, MAP3K19 PRKD3 213/4885MAP4K4 64/4885ERBB2 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.